Article
Oncology
Shinichiro Hasegawa, Hidenori Takahashi, Hirofumi Akita, Yosuke Mukai, Manabu Mikamori, Kei Asukai, Daisaku Yamada, Hiroshi Wada, Yoshiaki Fujii, Takahito Sugase, Masaaki Yamamoto, Tomohira Takeoka, Naoki Shinno, Hisashi Hara, Takashi Kanemura, Naotsugu Haraguchi, Junichi Nishimura, Chu Matsuda, Masayoshi Yasui, Takeshi Omori, Hiroshi Miyata, Masayuki Ohue, Osamu Ishikawa, Masato Sakon
Summary: This study evaluated the clinical implications of DUPAN-II as a biological indicator for pancreatic cancer during preoperative chemoradiation therapy. The normalization of DUPAN-II levels after CRT was found to be a significant prognostic factor and could predict treatment efficacy and patient prognosis.
Article
Oncology
Nana Kimura, Suguru Yamada, Hideki Takami, Kenta Murotani, Isaku Yoshioka, Kazuto Shibuya, Fuminori Sonohara, Yui Hoshino, Katsuhisa Hirano, Toru Watanabe, Hayato Baba, Kosuke Mori, Takeshi Miwa, Mitsuro Kanda, Masamichi Hayashi, Koshi Matsui, Tomoyuki Okumura, Yasuhiro Kodera, Tsutomu Fujii
Summary: The study aimed to investigate the optimal neoadjuvant therapy for borderline resectable pancreatic cancer, specifically in cases where the cancer invades the portal vein or abuts major arteries. It was found that using newer chemotherapy regimens is crucial for improving the prognosis of such pancreatic cancers.
Article
Oncology
Eva Versteijne, Jacob L. van Dam, Mustafa Suker, Quisette P. Janssen, Karin Groothuis, Janine M. Akkermans-Vogelaar, Marc G. Besselink, Bert A. Bonsing, Jeroen Buijsen, Olivier R. Busch, Geert-Jan M. Creemers, Ronald M. van Dam, Ferry A. L. M. Eskens, Sebastiaan Festen, Jan Willem B. de Groot, Bas Groot Koerkamp, Ignace H. de Hingh, Marjolein Y. Homs, Jeanin E. van Hooft, Emile D. Kerver, Saskia A. C. Luelmo, Karen J. Neelis, Joost Nuyttens, Gabriel M. R. M. Paardekooper, Gijs A. Patijn, Maurice J. C. van der Sangen, Judith de Vos-Geelen, Johanna W. Wilmink, Aeilko H. Zwinderman, Cornelis J. Punt, Geertjan van Tienhoven, Casper H. J. van Eijck
Summary: This study investigates the impact of neoadjuvant chemoradiotherapy on the survival of patients with resectable and borderline resectable pancreatic cancer. The results demonstrate that neoadjuvant chemoradiotherapy improves overall survival compared to upfront surgery in these patients.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Jin He, Richard D. Schulick, Marco Del Chiaro
Summary: The definition of BRPC should consider biological and conditional dimensions in addition to the anatomic relationship between the tumor and vessels. Neoadjuvant chemotherapy and surgery are associated with improved outcomes of BRPC.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Review
Oncology
Eva Versteijne, Ignace H. J. T. de Hingh, Marjolein Y. V. Homs, Martijn P. W. Intven, Joost M. Klaase, Hjalmar C. van Santvoort, Judith de Vos-Geelen, Johanna W. Wilmink, Geertjan van Tienhoven
Summary: There is a global shift towards a neoadjuvant approach for patients with resectable or borderline resectable pancreatic cancer. Randomized studies show that neoadjuvant chemotherapy or chemoradiotherapy improves overall survival. However, more effective chemotherapy regimens, such as FOLFIRINOX and Gemcitabine/Nab-paclitaxel, should be investigated in combination with radiotherapy to further improve outcomes.
FRONTIERS IN ONCOLOGY
(2022)
Review
Gastroenterology & Hepatology
Thomas F. Stoop, Rutger T. Theijse, Leonard W. F. Seelen, Bas Groot Koerkamp, Casper H. J. van Eijck, Christopher L. Wolfgang, Geertjan van Tienhoven, Hjalmar C. van Santvoort, I. Quintus Molenaar, Johanna W. Wilmink, Marco Del Chiaro, Matthew H. G. Katz, Thilo Hackert, Marc G. Besselink
Summary: Surgical resection combined with systemic chemotherapy is the main treatment approach for localized pancreatic cancer. Preoperative chemotherapy and radiotherapy are commonly used in cases with extensive vascular involvement. Treatment selection is based on anatomical, biological, and conditional parameters. Current guidelines and clinical practices vary in terms of preoperative therapy, response evaluation, and surgical decision-making.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
(2023)
Review
Oncology
Marco de Scordilli, Anna Michelotti, Diego Zara, Lorenza Palmero, Martina Alberti, Claudia Noto, Fabiana Totaro, Luisa Foltran, Michela Guardascione, Donatella Iacono, Elena Ongaro, Gianpiero Fasola, Fabio Puglisi
Summary: Surgery is the main treatment for non-metastatic pancreatic adenocarcinoma, but few patients are eligible for surgery at diagnosis. There are different treatment strategies for borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC) among different cancer centers. Preoperative chemotherapy is standard for both BRPC and LAPC patients, but there is still controversy regarding the specific treatment regimens, including type, dose, and duration, as well as the integration of radiotherapy or chemoradiation in the treatment plan. This study aims to review the current therapeutic regimens and literature data, compare available treatment options, explore new pharmacological agents, and analyze potential advancements in evaluating the microenvironment and selecting patients at a molecular level.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Article
Oncology
Roberto Alva-Ruiz, Lavanya Yohanathan, Jennifer A. Yonkus, Amro M. Abdelrahman, Lindsey A. Gregory, Thorvadur R. Halfdanarson, Amit Mahipal, Robert R. McWilliams, Wen Wee Ma, Christopher L. Hallemeier, Rondell P. Graham, Travis E. Grotz, Rory L. Smoot, Sean P. Cleary, David M. Nagorney, Michael L. Kendrick, Mark J. Truty
Summary: This study reviewed patients with borderline resectable/locally advanced pancreatic ductal adenocarcinoma who underwent neoadjuvant chemotherapy followed by either continued first-line chemotherapy or chemotherapy switch. The results showed that patients undergoing chemotherapy switch with subsequent curative-intent surgical resection did not have significantly different recurrence-free survival and overall survival compared to those receiving first-line chemotherapy. However, patients undergoing chemotherapy switch without subsequent resection had significantly worse overall survival.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Gastroenterology & Hepatology
Hironobu Suto, Keiichi Okano, Minoru Oshima, Yasuhisa Ando, Hiroyuki Matsukawa, Shigeo Takahashi, Toru Shibata, Hideki Kamada, Hideki Kobara, Akihito Tsuji, Tsutomu Masaki, Yasuyuki Suzuki
Summary: The neoadjuvant chemoradiotherapy with a 5-week regimen shows good clinical efficacy and safety for R- and BRV-PDAC, achieving better outcomes than the 2-week regimen for BRV-PDAC. However, both regimens achieve similar outcomes for R-PDAC.
Article
Surgery
Kevin M. Turner, Aaron M. Delman, Jordan R. Kharofa, Milton T. Smith, Kyuran A. Choe, Olugbenga Olowokure, Gregory C. Wilson, Sameer H. Patel, Davendra Sohal, Syed A. Ahmad
Summary: The role of radiation therapy in borderline resectable pancreatic cancer is still controversial. Although it may improve local control, the benefits in a disease marked by systemic failure are questioned. There is no clear survival benefit of radiation therapy in borderline resectable pancreatic cancer.
Article
Surgery
Jelle C. van Dongen, Mustafa Suker, Eva Versteijne, Bert A. Bonsing, J. Sven D. Mieog, Judith de Vos-Geelen, Erwin van der Harst, Gijs A. Patijn, Ignace H. de Hingh, Sebastiaan Festen, Albert J. Ten Tije, Olivier R. Busch, Marc G. Besselink, Geertjan van Tienhoven, Bas Groot Koerkamp, Casper H. J. van Eijck
Summary: Preoperative chemoradiotherapy does not increase the incidence of surgical complications in patients with (borderline-)resectable pancreatic cancer and can reduce the rate of postoperative pancreatic fistula.
Article
Oncology
Jacob L. van Dam, Quisette P. Janssen, Marc G. Besselink, Marjolein Y. Homs, Hjalmar C. van Santvoort, Geertjan van Tienhoven, Roeland F. de Wilde, Johanna W. Wilmink, Casper H. J. van Eijck, Bas Groot Koerkamp
Summary: This study found that neoadjuvant therapy can improve overall survival in patients with borderline resectable pancreatic cancer. However, more evidence is needed to determine whether it also improves survival in patients with resectable pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Yoichi Miyata, Naoto Yonamine, Ibuki Fujinuma, Takazumi Tsunenari, Yasuhiro Takihata, Hiroyuki Hakoda, Akiko Nakazawa, Toshimitsu Iwasaki, Takahiro Einama, Junichi Togashi, Hironori Tsujimoto, Hideki Ueno, Yoshifumi Beck, Yoji Kishi
Summary: This study investigated the impact of preoperative tumor size (TS) on surgical outcomes in patients with resectable pancreatic ductal adenocarcinoma (R-PDAC). The results showed that larger tumor size was associated with a higher rate of incomplete resection (R1) and worse prognosis. Therefore, tumor size should be considered when treating R-PDAC.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Surgery
Deesje Doppenberg, Jacob L. van Dam, Youngmin Han, Bert A. Bonsing, Olivier R. Busch, Sebastiaan Festen, Erwin van der Harst, Ignace H. de Hingh, Marjolein Y. Homs, Wooil Kwon, Mirang Lee, Daan J. Lips, Vincent E. de Meijer, I. Quintus Molenaar, Joost J. Nuyttens, Gijs A. Patijn, Stijn van Roessel, George P. van der Schelling, Mustafa Suker, Eva Versteijne, Judith de Vos-Geelen, Johanna W. Wilmink, Casper H. J. van Eijck, Geertjan van Tienhoven, Jin-Young Jang, Marc G. Besselink, Bas Groot Koerkamp
Summary: Two randomized controlled trials (RCTs) have shown that neoadjuvant chemoradiotherapy (CRT) is associated with better survival in patients with resectable and borderline resectable pancreatic cancers compared to upfront surgery. The baseline serum CA19-9 level does not affect the treatment effect of neoadjuvant CRT, indicating that it should not be withheld based on CA19-9 concentration.
BRITISH JOURNAL OF SURGERY
(2023)
Article
Surgery
Woohyung Lee, Minyoung Oh, Jae Seung Kim, Yejong Park, Jae Woo Kwon, Eunsung Jun, Ki Byung Song, Jae Hoon Lee, Dae Wook Hwang, Changhoon Yoo, Kyu-Pyo Kim, Jae Ho Jeong, Heung-Moon Chang, Baek-Yeol Ryoo, Seo Young Park, Song Cheol Kim
Summary: This study showed that decreased metabolic parameters of PET/CT after neoadjuvant chemotherapy were associated with improved survival and recurrence-free survival. Large delta values were related to a positive impact on recurrence. Post-neoadjuvant chemotherapy SUVmax >= 3 was an independent prognostic factor for negative impact on survival.
BRITISH JOURNAL OF SURGERY
(2022)
Article
Oncology
Takeshi Kado, Yoshito Tomimaru, Shogo Kobayashi, Hidenori Takahashi, Kazuki Sasaki, Yoshifumi Iwagami, Daisaku Yamada, Takehiro Noda, Yuichiro Doki, Hidetoshi Eguchi
Summary: This study demonstrates that GDA involvement is an independent factor significantly associated with postoperative survival in PDAC. Patients with GDA contact > 180 degrees have a poorer prognosis, which may be linked to the development of postoperative distant metastasis.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Shohei Takaichi, Yoshito Tomimaru, Shogo Kobayashi, Keisuke Toya, Kazuki Sasaki, Yoshifumi Iwagami, Daisaku Yamada, Takehiro Noda, Hidenori Takahashi, Tadafumi Asaoka, Masahiro Tanemura, Yuichiro Doki, Hidetoshi Eguchi
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Shohei Takaichi, Yoshito Tomimaru, Shogo Kobayashi, Keisuke Toya, Kazuki Sasaki, Yoshifumi Iwagami, Daisaku Yamada, Takehiro Noda, Hidenori Takahashi, Tadafumi Asaoka, Masahiro Tanemura, Yuichiro Doki, Hidetoshi Eguchi
Summary: This study investigated the impact of changes in body composition on postoperative outcomes in patients with PDAC undergoing neoadjuvant chemoradiotherapy. The results showed that loss of skeletal muscle mass during NACRT was an independent risk factor for survival in PDAC patients.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Shinichiro Hasegawa, Hidenori Takahashi, Hirofumi Akita, Yosuke Mukai, Manabu Mikamori, Kei Asukai, Daisaku Yamada, Hiroshi Wada, Yoshiaki Fujii, Takahito Sugase, Masaaki Yamamoto, Tomohira Takeoka, Naoki Shinno, Hisashi Hara, Takashi Kanemura, Naotsugu Haraguchi, Junichi Nishimura, Chu Matsuda, Masayoshi Yasui, Takeshi Omori, Hiroshi Miyata, Masayuki Ohue, Osamu Ishikawa, Masato Sakon
Summary: This study evaluated the clinical implications of DUPAN-II as a biological indicator for pancreatic cancer during preoperative chemoradiation therapy. The normalization of DUPAN-II levels after CRT was found to be a significant prognostic factor and could predict treatment efficacy and patient prognosis.
Article
Immunology
Keisuke Toya, Yoshito Tomimaru, Shogo Kobayashi, Akima Harada, Kazuki Sasaki, Yoshifumi Iwagami, Daisaku Yamada, Takehiro Noda, Hidenori Takahashi, Takeshi Kado, Hiroki Imamura, Shohei Takaichi, Ryota Chijimatsu, Tadafumi Asaoka, Masahiro Tanemura, Shigeru Miyagawa, Yuichiro Doki, Hidetoshi Eguchi
Summary: This study demonstrates that autologous skeletal myoblast cell sheet transplantation can promote liver cell proliferation, angiogenesis, and suppress the activation of hepatic stellate cells. In vivo experiments showed that sheet transplantation significantly inhibited liver fibrosis and accelerated liver regeneration, suggesting that it could be a potential therapeutic option for liver regeneration in liver failure.
Article
Immunology
Daiki Hokkoku, Yoshito Tomimaru, Shogo Kobayashi, Toshinori Ito, Kazuki Sasaki, Yoshifumi Iwagami, Daisaku Yamada, Takehiro Noda, Hidenori Takahashi, Yuichiro Doki, Hidetoshi Eguchi
Summary: Due to limited organ donations from deceased donors in Japan, pancreas grafts for pancreas transplantation (PTx) are often harvested from the same donor surgery as the liver graft. This study investigated the clinical significance of gastroduodenal artery (GDA) reconstruction using an interposition graft (I-graft) in maintaining blood flow to the pancreas graft in patients after PTx.
TRANSPLANTATION PROCEEDINGS
(2023)
Article
Immunology
Yoshito Tomimaru, Shogo Kobayashi, Toshinori Ito, Kazuki Sasaki, Yoshifumi Iwagami, Daisaku Yamada, Takehiro Noda, Hidenori Takahashi, Yuichiro Doki, Hidetoshi Eguchi
Summary: This study investigated the clinical usefulness of placing a decompression tube (DT) for prevention of duodenal graft perforation (DGP) during pancreas transplantation (PTx). The results showed that there was no significant difference in DGP incidence between the DT group and the non-DT group. However, adverse effects related to DT placement were observed in some cases. Therefore, the placement of DT may not have a clinical impact on DGP prevention after PTx.
TRANSPLANTATION PROCEEDINGS
(2023)
Meeting Abstract
Oncology
Keisuke Oyama, Yoshifumi Iwagami, Shogo Kobayashi, Kazuki Sasaki, Daisaku Yamada, Yoshito Tomimaru, Takehiro Noda, Hidenori Takahashi, Yuichiro Doki, Hidetoshi Eguchi
Meeting Abstract
Oncology
Hiromichi Sato, Kazuki Sasaki, Yasuko Arao, Mika Nakayama, Yu Takeda, Daisaku Yamada, Yoshito Tomimaru, Norikatsu Miyoshi, Hidenori Takahashi, Shogo Kobayashi, Masaki Mori, Yuichiro Doki, Hidetoshi Eguchi, Hideshi Ishii
Meeting Abstract
Oncology
Hiromichi Sato, Kazuki Sasaki, Yasuko Arao, Mika Nakayama, Yu Takeda, Daisaku Yamada, Yoshito Tomimaru, Norikatsu Miyoshi, Hidenori Takahashi, Shogo Kobayashi, Masaki Mori, Yuichiro Doki, Hidetoshi Eguchi, Hideshi Ishii
Meeting Abstract
Oncology
Yu Takeda, Ryota Chijimatsu, Shogo Kobayashi, Masatoshi Kitakaze, Daisaku Yamada, Hidenori Takahashi, Masaki Mori, Yuichiro Doki, Hidetoshi Eguchi, Hideshi Ishii
Meeting Abstract
Oncology
Matoba Daijiro, Yoshihiro Sakano, Takehiro Noda, Shogo Kobayashi, Kazuki Sasaki, Yoshifumi Iwagami, Daisaku Yamada, Yoshito Tomimaru, Hidenori Takahashi, Yuichiro Doki, Hidetoshi Eguchi
Meeting Abstract
Oncology
Kazuya Kato, Takehiro Noda, Shogo Kobayashi, Kazuki Sasaki, Yoshifumi Iwagami, Daisaku Yamada, Yoshito Tomimaru, Hidenori Takahashi, Yuichiro Doki, Hidetoshi Eguchi
Meeting Abstract
Gastroenterology & Hepatology
Keisuke Toya, Yoshito Tomimaru, Shogo Kobayashi, Akima Harada, Kazuki Sasaki, Yoshifumi Iwagami, Daisaku Yamada, Takehiro Noda, Hidenori Takahashi, Ryota Dhijimatsu, Shigeru Miyagawa, Yuichiro Doki, Hidetoshi Eguchi
JOURNAL OF HEPATOLOGY
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Daiki Hokkoku, Kazuki Sasaki, Shogo Kobayashi, Yoshifumi Iwagami, Daisaku Yamada, Yoshito Tomimaru, Takehiro Noda, Hidenori Takahashi, Yuichiro Doki, Hidetoshi Eguchi
JOURNAL OF HEPATOLOGY
(2023)
